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ARTICLE OPEN
LncRNA RP11-19E11 is an E2F1 target required for
proliferation and survival of basal breast cancer
A. Giro-Peraﬁta 1, L. Luo1, A. Khodadadi-Jamayran2, M. Thompson1, B. Akgol Oksuz2,4, A. Tsirigos 2,3, B. D. Dynlacht3, I. Sánchez3* and
F. J. Esteva1*
Long non-coding RNAs (lncRNAs) play key roles in the regulation of breast cancer initiation and progression. LncRNAs are
differentially expressed in breast cancer subtypes. Basal-like breast cancers are generally poorly differentiated tumors, are enriched
in embryonic stem cell signatures, lack expression of estrogen receptor, progesterone receptor, and HER2 (triple-negative breast
cancer), and show activation of proliferation-associated factors. We hypothesized that lncRNAs are key regulators of basal breast
cancers. Using The Cancer Genome Atlas, we identiﬁed lncRNAs that are overexpressed in basal tumors compared to other breast
cancer subtypes and expressed in at least 10% of patients. Remarkably, we identiﬁed lncRNAs whose expression correlated with
patient prognosis. We then evaluated the function of a subset of lncRNA candidates in the oncogenic process in vitro. Here, we
report the identiﬁcation and characterization of the chromatin-associated lncRNA, RP11-19E11.1, which is upregulated in 40% of
basal primary breast cancers. Gene set enrichment analysis in primary tumors and in cell lines uncovered a correlation between
RP11-19E11.1 expression level and the E2F oncogenic pathway. We show that this lncRNA is chromatin-associated and an E2F1
target, and its expression is necessary for cancer cell proliferation and survival. Finally, we used lncRNA expression levels as a tool
for drug discovery in vitro, identifying protein kinase C (PKC) as a potential therapeutic target for a subset of basal-like breast
cancers. Our ﬁndings suggest that lncRNA overexpression is clinically relevant. Understanding deregulated lncRNA expression in
basal-like breast cancer may lead to potential prognostic and therapeutic applications.
npj Breast Cancer             (2020) 6:1 ; https://doi.org/10.1038/s41523-019-0144-4
INTRODUCTION
Breast cancer is the most frequently diagnosed malignancy in
women worldwide and is the second leading cause of cancer-
related death in the United States.1 Expression of the estrogen
receptor (ER), progesterone receptor (PR), and ampliﬁcation of the
HER2 gene deﬁne the main breast cancer subtypes in terms of
prognostic and therapeutic intervention. Gene expression proﬁl-
ing based on complementary DNA (cDNA) microarrays led to the
classiﬁcation of breast cancer into distinct subtypes, with separate
prognostic and treatment implications: luminal A (LA), luminal B
(LB), basal-like (BL), and Her2-enriched (HER2).2,3 The PAM50 assay
measures the messenger RNA (mRNA) expression levels of 50
genes that can classify breast cancers into the same subtypes.
Triple-negative breast cancer (TNBC), deﬁned as lacking expres-
sion of ER/PR/HER2 receptors, represents 15–20% of breast cancer,
and it is associated with the highest probability of relapse among
breast cancer subtypes despite local treatments and cytotoxic
chemotherapy.4 The majority of TNBCs are classiﬁed as BL and vice
versa, with an overlap between the two classiﬁcations of ~80%.5
The broad heterogeneity of TNBC, both inter- and intra-tumoral,
has contributed to the difﬁculties in successfully treating it.
Indeed, gene expression proﬁling performed in triple-negative
breast cancers displayed six independent clusters with speciﬁc
ontology, including two BL (BL1 and BL2), immunomodulatory
(IM), mesenchymal, mesenchymal stem-like (MSL), and luminal
androgen receptor (LAR)6 subtypes.
With the development and improvement of genomic sequen-
cing with high-throughput technologies, we have learned that
while most of the genome is transcribed (96–98%), ~2% of these
transcripts encode for proteins.7 Although most of these non-
coding transcripts have been considered junk DNA historically, in
the past few decades, non-coding RNAs have been implicated in a
variety of normal biological processes and disease states.8,9
Furthermore, the number of non-coding elements increases more
rapidly than protein coding genes (PCG) with increasing
organismal complexity.10 In addition, a high proportion of
disease-related genetic variants identiﬁed with genome-wide
association studies (GWAS) map to non-coding regions, suggest-
ing a biological role for these transcripts in health and disease.11
Long non-coding RNAs (lncRNAs) are a large and diverse class of
non-coding RNA transcripts with a length ≥200 nucleotides.
LncRNA expression has been implicated in a variety of biological
processes, ranging from development and cell cycle control to
apoptosis and carcinogenesis.8,9 Emerging lncRNA functional
mechanisms are diverse and versatile; lncRNAs may act as guides,
decoys, or scaffolds for chromatin modeling complexes, regulate
post-transcriptional mRNA decay, or act as sponges for miRNA and
regulate mRNA splicing, among other functions.12 We and others
have shown that the lncRNA landscape in breast cancer is subtype-
speciﬁc. Using unsupervised clustering analysis, lncRNA expression
can classify breast cancers similarly to PCG expression.13,14
Additionally, accumulating evidence indicates that several lncRNAs
are involved speciﬁcally in breast carcinogenesis.13,15
In the present study, we sought to identify clinically relevant
lncRNAs deregulated speciﬁcally in basal-like breast cancer
patients and then functionally evaluated a subset of these
candidates in the oncogenic process in vitro and assessed their
value as prognostic markers. We identiﬁed and characterized the
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chromatin-associated lncRNA, RP11-19E11.1, which is upregulated
in 40% of basal primary breast cancers. Gene set enrichment
analysis (GSEA) in primary tumors and in cell lines uncovered a
correlation between RP11-19E11.1 expression level and the E2F
oncogenic pathway. We show that this lncRNA is chromatin-
associated and an E2F1 target, and its expression is necessary for
cancer cell proliferation. Finally, we used lncRNA expression levels
as a tool for drug discovery in vitro and identiﬁed PKC as a
potential therapeutic target for a subset of BL breast cancers.
RESULTS
Identiﬁcation of clinically relevant lncRNAs overexpressed
speciﬁcally in BL breast cancer
In order to identify lncRNAs that play a role in BL breast cancer, we
used RNA-sequencing (RNA-seq) data from 1183 patients available
in the The Cancer Genome Atlas (TCGA) database. We classiﬁed
the tumors with available PAM50 molecular subtype annotation,16
obtaining a ﬁnal cohort of 769 patients represented by 131 BL, 64
HER2, 404 LA, and 170 LB subtypes (Fig. 1a). We excluded 25
tumors initially classiﬁed as normal-like (NL) subtype for further
analysis. We and others have previously shown that lncRNA
expression reﬂects subtype speciﬁcity in breast cancer.13,14,17
Accordingly, t-SNE (t-distributed stochastic neighbor embedding)
analysis of the top 500 lncRNAs expressed in patients showed a
molecular subtype-based clustering for this cohort of patients,
similar to the one obtained using marker genes, a mix between
coding and non-coding genes (Fig. 1b, Supplementary Fig. 1a).
Using differentially expressed gene analysis (DEseq analysis), we
identiﬁed a subset of lncRNAs overexpressed in the BL subtype
(>1.5-fold change) compared to normal tissue and other subtypes.
To enrich for clinically relevant lncRNAs, we ﬁltered out those with
low baseMean (<0.5) expressed in fewer than 10% of the patients.
To study their function in vitro, we analyzed the RNA-seq data of a
panel of cell lines and selected those lncRNAs that were expressed
in at least two BL breast cancer cell lines. To further restrict the list
of potential lncRNAs overexpressed in BL breast cancer, we
selected the genes that were highly expressed in BL breast cancer
and minimally expressed in the other subtypes (cut-off was <15%
of patients with FPKM (fragments per kilobase of exon model per
million reads mapped) >1) (Fig. 1c, d). Interestingly, this produced
a list of nine candidates, expression of which was sufﬁcient to
cluster the BL subtype tumors by t-SNE analysis (Supplementary
Fig. 1b).
In vitro validation and functional screening of lncRNAs
overexpressed in BL breast cancer
To study potential roles of these lncRNAs in tumor growth or
cancer progression using in vitro models, we analyzed their levels
in cell lines representing different molecular subtypes of breast
cancer with Quantitative reverse transcription PCR (qRT-PCR). We
selected for further studies those lncRNAs showing detectable
levels by qRT-PCR and overexpression (OE) of at least ten-fold in at
least two BL cell lines compared to other subtypes of cancer and/
or normal breast cell lines. LncRNAs CTD-2015G9.2, RP11-19E11.1,
AC01917.1, and RP3-522D1.1 fulﬁlled these criteria, and since their
expression patterns in cell lines mirrored those observed in
patients, they were selected for further functional studies (Figs 1e
and 2a). We next examined the localization of these lncRNAs as
this could provide insight into their potential functions. Three of
the four candidates showed mostly cytoplasmic localization
(similar to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)),
while RP11-19E11.1 exhibited strong nuclear localization, similar to
levels observed for nuclear non-coding RNA (ncRNA) controls,
MALAT-1 and 7SK. (Fig. 2b). Using the patient survival data
available in TGCA, we asked whether any of our candidates would
behave as a prognostic marker. We divided the patients into high
and low expression groups for each of the four candidates and
performed log-rank test (Supplementary Fig. 2). Patients with
higher levels of the lncRNA AC01917.1 had somewhat better
survival proﬁles (p value 0.035), whereas patients with high levels
of RP11-19E11.1 exhibited poor survival outcomes (p value 0.041).
We then asked if any of these lncRNAs played a role in cancer cell
growth and migration. To assess this, we designed small
interfering RNAs (siRNAs) for the cytoplasmic lncRNAs and locked
nucleic acid (LNA) GapmeRs (LNAs) to knock down the nuclear
lncRNA. Initially, we measured cell viability after transcript knock-
down using two different cell lines that overexpressed the lncRNA
candidates (Fig. 2c, d). Of note, viability was reduced in all cell lines
depleted of CTD-2015G9, RP11-19E11.1, or RP3-522D1.1, but there
was no effect observed after knock-down of AC01917.1. We
therefore tested whether this lncRNA might be important in cell
migration and/or invasion (Fig. 2e) and found that knock-down of
AC01917.2 in two different cell lines impaired migration and
invasion in Boyden chamber migration assays.
Thus, our studies indicate that we have identiﬁed a small group
of lncRNA candidates with BL subtype-speciﬁc expression in both
patients and cell lines. Importantly, our ability to cluster BL tumors
based on this proﬁle suggests that these lncRNAs could have
prognostic value and play a potential role in tumor development
and carcinogenesis.
Genetic characterization of the BL-speciﬁc and chromatin-
associated lncRNA RP11-19E11.1
The nuclear lncRNA, RP11-19E11.1, is overexpressed in 40% of BL
patients. We showed that cell viability was strongly impaired after
knock-down and that patients with high levels of this lncRNA have
a poor prognosis. Therefore, we sought to characterize its
potential function in depth and focused on this lncRNA in the
remainder of our study.
RP11-19E11.1 is an intragenic lncRNA. The annotation for this
lncRNA identiﬁed two variants of the transcript with different 5′
and 3′ ends (Fig. 3a). In order to verify the authentic 5′ and 3′ ends
of this lncRNA, we performed 5′ and 3′ rapid ampliﬁcation of cDNA
ends (RACE) using the nuclear fraction of a cell line that highly
expresses this lncRNA (HCC2157). Our results showed that in
contrast with previous annotations, variants 1 and 2 (V1 and V2)
share the same 3′ end (Fig. 3a). Further, we were not able to detect
any transcripts with the 5′ end of annotated V2, while two
different isoforms with the same introns as V2 shared the 5′ end of
V1 (Fig. 3a). Sequencing results of the RACE clones showed that all
the variants incorporated 85 additional nucleotides at the 5′ end
of the annotated V1.
We next explored whether this lncRNA is associated with
chromatin, as many nuclear lncRNAs have been reported to play a
role in chromatin remodeling or transcriptional regulation, among
other functions.18,19 Our results clearly indicated chromatin
association, similar to Neat-1 or Xist, used as controls for both
V1 and V2 (Fig. 3b). Nuclear lncRNAs can regulate expression of
neighboring genes in cis. To investigate this hypothesis, we
plotted a heatmap for the expression of all genes found in a 1 Mb
window around the lncRNA (Fig. 3c). Strikingly, we observed a
near-perfect correlation in expression between RP11-19E11.1 and
EN1, a neural-speciﬁc transcription factor localized ~13 kb away
that was implicated in basal-like breast cancer.20 This correlation
was also observed in multiple cell lines (Fig. 3d). However, after
knock-down of the lncRNA, we did not observe a signiﬁcant
change in the expression of neighboring genes, including EN1
(Fig. 3e). Moreover, knock-down of EN1 did not signiﬁcantly
change RP11-19E11.1 expression (Supplementary Fig. 3a). We also
noted that OE of both transcripts was not due to an ampliﬁcation
of this region on the chromosome (cBioportal). Since both
promoters of RP11-19E11.1 and EN1 are enriched for CpG islands,
we speculated that the observed co-OE could be due to
A. Giro-Peraﬁta et al.
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deregulation of DNA methylation in the promoter of these two
transcripts. Using TCGA methylation data, we found that the
percentage of methylated CpG islands in this region was
signiﬁcantly lower for triple-negative patients than the other
subtypes of cancer or normal tissue (Supplementary Fig. 3b). DNA
methylation is an essential layer of regulation in mammalian
genomes, controlling several biological processes, including
development. Patterns of DNA methylation are profoundly altered
in cancer, both by suppressing the transcription of tumor
suppressor genes by promoter hypermethylation and by activat-
ing gene transcription due to global hypomethylation.21 Our data
suggest that expression of RP11-19E11.1 could be deregulated
in a subset of basal tumors as a result of hypomethylation of a
large chromosomal region that includes this lncRNA. Since all
Fig. 1 Identiﬁcation of lncRNAs speciﬁc for the basal-like breast cancer subtype using patient data from the TCGA database. a Pipeline
ﬂow chart used to identify lncRNA candidates. b t-SNE plot originated from the expression of the 500 top-expressed lncRNA in patients.
c Heatmap showing the expression of the nine lncRNA candidates in different breast cancer subtypes. d Heatmap showing the expression of
the nine candidates in a panel of cell lines classiﬁed according to their molecular subtype. e Dot plot showing the levels of expression for each
patient within the breast cancer subtypes for the lncRNA candidates selected. Mean ± SD are represented for each condition. *P < 0.05; **p <
0.01; ***p < 0.001 (ANOVA). NT normal tissue, BL basal-like, HER2 her2-enriched, LA luminal A, LB luminal B, NL normal-like.
A. Giro-Peraﬁta et al.
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Fig. 2 In vitro validation and functional screening of lncRNA candidates. a RNA expression obtained by qRT-PCR for four of the lncRNA
candidates in a panel of cell lines. MCF7 cell line was used as reference. b Subcellular localization of the lncRNA candidates assessed by qRT-
PCR after nuclear–cytoplasm fractionation. c Viability assays (MTT) after knock-down (siRNA 20 nM or LNA 50 nM) in two different cell lines for
each of the lncRNA candidates at different time points. d RNA levels of the lncRNA candidates after knock-down in two cell lines at 48 and
72 h after transfection. e Migration and invasion in the MDA-MB-468 cell line after lncRNA AC01719.1 knock-down. Experiments were
performed at least three times in triplicate. Data are presented as mean ± SEM. *P < 0.05; **p < 0.01; ***p < 0.001 (two-tailed unpaired t test).
A. Giro-Peraﬁta et al.
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RP11-19E11.1 transcripts identiﬁed show nuclear localization and
chromatin association, we propose that the function of this
lncRNA is linked to regulation of chromatin-associated processes.
Patients with high RP11-19E11.1 show speciﬁc oncogenic
signature
Since patients with high levels of RP11-19E11.1 have a poorer
prognosis than those exhibiting lower expression, we asked if
patients that overexpress RP11-19E11.1 share a speciﬁc oncogenic
signature. To that end, we compared BL patients with high and
low RP11-19E11.1 expression (1Q vs. 4Q, n= 33 for each group)
using GSEA (Fig. 4a). Intriguingly, patients with high levels of RP11-
19E11.1 showed signiﬁcant downregulation of the hallmark
phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin
signaling pathway and upregulation of the RB/E2F oncogenic
pathway (Fig. 4b, c). We then evaluated if there was any alteration
in some of the principal effectors of this axis commonly
deregulated in cancer (RB, E2F, CDKN2A, CCDN1, CDK4) by
ampliﬁcation, deletion, or mutation that could be associated with
the expression pattern of the lncRNA22 (Fig. 4d). Deregulation of
this pathway is known to be prevalent in breast cancer and is
connected to poor outcome.23 We did not ﬁnd signiﬁcant
differences between patients with high and low RP11-19E11.1 in
the prevalence of any gene alterations that can activate these
pathways (Fig. 4d, e). As patients with high RP11-19E11.1 show a
speciﬁc oncogenic signature, we analyzed whether the expression
of this lncRNA was restricted to a unique TNBC molecular subtype,
as deﬁned by another well-established classiﬁcation scheme.6,24
The stratiﬁcation of 102 TNBC patients in these six different
subtypes showed a signiﬁcant enrichment of RP11-19E11.1 in the
BL1 subtype (Fig. 4f). The BL1 is a subtype enriched in cell cycle
and cell division components and pathways, showing increased
proliferation and cell cycle check point loss. These results align
well with our GSEA analysis. Furthermore, we also observed that
this lncRNA was also highly expressed in the subtypes IM and
mesenchymal, both subtypes having highly proliferative pheno-
types compared to BL2, MSL, or LAR.
These results suggest that factors other than genetic back-
ground trigger the E2F oncogenic signature and that this
signature correlates with poor prognosis in BL breast cancer.
lncRNA RP11-19E11.1 knock-down induces cell cycle arrest and
apoptosis
We extended our analysis of a panel of BL cell lines to study the
levels of both variants of the lncRNA RP11-19E11.1. We also
performed viability assays (MTT, 3-(4-5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) with two different LNAs separately,
targeting different regions and variants of this lncRNA in two
different cell lines, HCC38 (viability at 72 h for LNA2 vs. LNA NS
p value 0.017, for LNA3 vs. LNA NS p value < 0.001) and SUM149PT
Fig. 3 LncRNA RP11-19E11.1 transcript characterization. a Scheme representing 5′ and 3′ RACE results for the three main variants identiﬁed.
b Subcellular localization of V1 and V2 assessed by qRT-PCR after nuclear–cytoplasm fractionation and chromatin precipitation. Data are
presented as mean value ± SEM. c Heatmap of the expression of 1 Mb neighboring genes of lncRNA RP11-19E11.1 in TCGA patients.
d Heatmap of the expression of RP11-19E11.1 and EN1 in a panel of cell lines. e Dot plot showing the expression levels of RP11-19E11.1
neighboring genes for each cell line. For each gene mean ± SD is represented. Value not shown for those genes in which expression was
below detection level. Experiments were performed at least three times in triplicate.
A. Giro-Peraﬁta et al.
5
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2020)     1 
Fig. 4 GSEA analysis of basal-like patients with high (n= 33) vs. low (n= 33) expression levels of RP11-19E11.1. a Heatmap of top and
bottom ranked genes in patients with high and low RP11-19E11.1. b GSEA enrichment results for hallmark repository. c GSEA enrichment
results for Oncogenic pathways. d Gene alteration in E2F axis in patients with high (n= 33) or low (n= 33) RP11-19E11.1 levels or within the
basal-like subtype (labeled as basal). e Heatmap of E2F- and E2F-regulated genes in breast cancer subtypes. f Dot plot showing the expression
of RP11-19E11.1 for each patient within the molecular subtypes identiﬁed by Vanderbilt classiﬁcation in 102 TNBC patients from TCGA
(Mann–Whitney test). Mean ± SEM is presented for each condition. *P < 0.05; **p < 0.01; ***p < 0.001. HD homodeletion, M mutation, AMP
ampliﬁcation.
A. Giro-Peraﬁta et al.
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(viability at 72 h for LNA2 vs. LNA NS p value 0.002, for LNA2 vs.
LNA NS p value < 0.001) (Fig. 5a, b). We found that knock-down
was most efﬁcient 18 h after transfection (>90% for LNA3, ~80%
for LNA2). In addition, we observed that both variants were down-
regulated after knock-down, irrespective of which LNA was used,
suggesting that they could target the unspliced transcript
(Supplementary Fig. 4). We next performed RNA-seq after
transfection of LNAs targeting RP11-19E11.1 in three cell lines.
489 genes were commonly deregulated in all three cell lines (fold-
change >2 and false discovery rate <0.1, Fig. 5c). In order to
A. Giro-Peraﬁta et al.
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identify the main pathways that may be linked to the lncRNA
function, we performed GSEA analysis and evaluated enrichment
of oncogenic pathways and transcription factor motifs in
deregulated genes. Interestingly, our analysis showed that E2F/
Rb oncogenic pathways and genes enriched for the E2F
transcription factor motif were lost after RP11-19E11.1 knock-
down (Fig. 5d). In contrast, gene sets that showed upregulation
included the p53 pathway, ultraviolet (UV) response, and tumor
necrosis factor-α signaling via nuclear factor-κB) (Fig. 5d).
In light of these transcriptomic changes, we analyzed DNA
damage markers (γH2AX) and p53 pathway proteins by western
blotting after RP11-19E11.1 knock-down. We observed substantial
induction of γH2AX after 18 h. Also, p53 levels increased after the
knock-down, in concert with its canonical target, p21/CDKN1A
(Fig. 5e). Upregulation of other canonical p53 target genes, GADD45
and PMAIP1/Noxa, was also observed after knock-down in both cell
lines (Supplementary Fig. 5a). Accordingly, cell cycle analysis showed
a concomitant decrease in the S-phase fraction in all cell lines
(HCC38 p value 0.017, SUM149PT p value 0.002), and a G2/M phase
block for SUM149PT cells (p value < 0.001), conﬁrmed also by DNA
synthesis inhibition measured by active 5-ethynyl-2′-deoxyuridine
(EdU) incorporation (HCC38 p value 0.0011, SUM149PT p value
0.0014) (Fig. 5f). Given the apparent activation of p53 target genes
and the DNA damage response, we asked whether apoptosis could
be induced in cells depleted of this lncRNA. Indeed, apoptosis
analysis using Annexin-V staining showed induction of cell death
within 48 h of knock-down (Fig. 5g) in both cell lines.
These observations strongly connected our GSEA analysis with
phenotypes described after RP11-1E11.1 knock-down, namely, E2F
downregulation and cell cycle arrest, followed by activation of
apoptotic pathways. We surmise that the resultant apoptosis
could be due to replication stress or induction of the DNA damage
response after RP11-19E11.1 knock-down.
The induction of p53 downstream genes occurs in a partially p53-
independent manner
p53 mutations have been reported in >80% of triple-negative
breast cancers.25 Most of the mutations are localized to the DNA
binding domain, perturbing the afﬁnity of p53 for the promoter
and altering the expression of transcriptional target genes.26 We
noticed that HCC1569, a p53-null cell line, shows high levels of
RP11-1911.1, and therefore we asked whether the knock-down of
the lncRNA could induce the same response in p53 target genes.
Unexpectedly, p21 levels were upregulated independently of p53
in this cell line (Supplementary Fig. 5b, c). Similar results were
obtained with the p53-mutated SUM149PT cell line. The depletion
of p53 in this cell line did not rescue cell viability after lncRNA
knock-down, and levels of p21 increased both at the RNA and
protein level independently of p53 protein levels (Supplementary
Fig. 5b, d, e). Therefore, apoptosis induction can occur indepen-
dently of p53 function, which is relevant for a subtype of breast
cancer with a high frequency of p53 mutations.
lncRNA RP11-19E11.1 is a E2F1 target gene
Patients with high levels of expression of RP11-1E11.1 have a
speciﬁc gene signature related to activation of a subset of E2F
target genes. Indeed, the loss of this lncRNA induces cell cycle
arrest, thereby reducing proliferation and, subsequently, inducing
apoptosis genes. Therefore, we examined three possible scenarios
that which could link this lncRNA with the E2F gene signature.
First, the lncRNA could control E2F1 transcription. Second, the
lncRNA could be regulated by E2F transcription family members
and therefore have an indispensable role in maintaining cell
proliferation, or third, the lncRNA is involved in regulation of a
speciﬁc subset of E2F downstream genes. The second and third
possibilities are not mutually exclusive.
To evaluate the ﬁrst option, we checked the levels of the E2F
family after RP11-1E11.1 knock-down using the RNA-seq data from
three different cell lines. The results did not show signiﬁcant
changes in RNA in any of the E2F family members (Fig. 6a). Protein
levels for E2F1 and E2F3 were also evaluated, and no signiﬁcant
changes were observed (Fig. 6b). Therefore, we next evaluated the
possibility of the lncRNA being an E2F target gene. Promoter
analysis identiﬁed several potential E2F motifs around the TSS
(transcription starting site) of the lncRNA (p value < 0.001, Fig. 6c). To
validate the hypothesis of a direct interaction of E2F1 with the
RP11-19E11.1 promoter, we performed chromatin immunoprecipita-
tion (ChIP) analysis. As several putative binding sites were identiﬁed,
we designed six overlapping primers sets that spanned regions
upstream and downstream of the TSS identiﬁed by 5′ RACE. Only
primer set 4 (−141+ 13 around TSS) showed signiﬁcant enrichment
compared to the control (p value 0.003) (Fig. 6d). Concordantly,
exogenous expression of E2F1 increased the expression of RP11-
19E11.1 (p value 0.04) to an extent similar to another canonical E2F1
target gene, CCNE2 (p value 0.017) (Fig. 6e).
Finally, regarding the possibility of RP11-19E11.1 regulating E2F
family target genes, we have shown in this study that RP11-19E11.1
depletion is followed by a reversal in the E2F gene signature in vitro,
and a robust induction of DNA damage, block of DNA synthesis, and
activation of apoptosis pathways. Therefore, we cannot exclude the
contribution of an indirect downregulation of some E2F target
genes due to a loss of cell ﬁtness after RP11-19E11.1 depletion.
Analyses beyond the scope of this report will help deﬁne the role of
this lncRNA in the regulation of genes controlled directly or
indirectly by the E2F transcription factor family.
E2F family members are well-known transcription factors that
control several aspects of cell proliferation, from cell cycle
progression to DNA damage checkpoints and repair. Several
lncRNAs have been identiﬁed as E2F targets, including H19,27
ANRIL,28 and ERIC,29 and all of them have been shown to exhibit
aberrant expression in tumor cells and to play important roles in
cancer development. We propose that RP11-19E11.1 may be
another member of this group of lncRNAs.
LncRNA RP11-19E11.1 expression has predictive value for drug
sensitivity in BL cell lines
Patients with high levels of the lncRNA show speciﬁc gene
signatures within the BL subtype. We therefore asked whether
drug sensitivity within the BL subtype could be predicted by the
levels of expression of the lncRNA RP11-19E11.1. To that end, we
explored the sensitivity of a selected panel of BL cell lines with
different levels of expression of the lncRNA to more than 267
Fig. 5 Functional characterization of lncRNA RP11-19E11.1. a RNA levels of both V1 and V2 assessed by qRT-PCR in a panel of basal-like cell
lines. MCF10A was used as a reference. b Viability assay (MTT) in HCC38 and SUM149PT cell lines using two different LNAs with distinct target
sites (LNA2/LNA3 25 nM). c Venn diagram of genes commonly deregulated (fold-change >2, false discovery rate (FDR) <0.1) in the three cell
lines after 24 h of knock-down (LNA1+ LNA2 50 nM). d GSEA enrichment results for hallmark and oncogenic pathways after the knock-down
of lncRNA RP11-19E11.1. e Protein analysis by WB of γH2AX, P53, p-P53, and p21 after 18 and 24 h after LNA3 transfection (25 nM). f Cell cycle
analysis and EdU incorporation analysis (PI-EdU double staining) at 24 h after LNA3 transfection (25 nM) in HCC38 and SUM149PT cell lines.
Each point represents a single measurement. g Annexin-V analysis after 24 and 48 h after LNA3 transfection (25 nM) in HCC38 and SUM149PT
cell lines. Experiments were performed at least three times in triplicate. Data are presented as mean ± SEM. *P < 0.05; **p < 0.01; ***p < 0.001
(two-tailed unpaired t test).
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compounds available from The Genomics of Drug Sensitivity in
Cancer.30 We found drug sensitivity screening data for 14 BL cell
lines and overlapped these data with the respective expression
levels of the lncRNA obtained from the RNA-seq data available in
the CCLE.31 We ranked the four top and four bottom cell lines
according to the expression of RP11-19E11.1 and compared
the average half-maximal inhibitory concentration (IC50) of the
high expressing cell lines to the average IC50 of the lowest ones
(Fig. 7a). We selected for further analysis those drugs that showed
an IC50
high/IC50
low ratio <0.25, to ensure biological signiﬁcance in
drug sensitivity between groups. For those compounds that
showed an IC50 signiﬁcantly different when comparing the six top/
bottom cell lines according to the lncRNA expression, we analyzed
if there was a correlation between drug sensitivity and levels of
expression of the lncRNA (Fig. 7b, c). Interestingly, three of the
compounds showed a signiﬁcant negative correlation between
expression levels and sensitivity: PAC-1 (p value 0.022), enzastaurin
(p value 0.023), and YM201636 (p value 0.023) (Fig. 7c). PAC-1 is
the ﬁrst pro-caspase activator compound developed and was
designated as an orphan drug by the Food Drug Administration in
2016.32 Enzastaurin is an inhibitor of the protein kinase C (PKC),
which failed the phase III treatment for the treatment of
lymphoma.33 YM201636, is a PIKfyve (phosphatidylinositol phos-
phate kinase PIP5KIII) inhibitor, a kinase implicated in PtdIns(3,5)P2
biosynthesis that regulates a number of intracellular membrane
Fig. 6 LncRNA RP11-19E11.1 is an E2F target gene. a RNA expression fold-change of E2F family transcription factors after RP11-19E11.1
knock-down from RNA-seq data. Each point represents the fold-change in each cell line, and for each gene mean value ± SD is represented.
b Western blot for E2F1 and E2F3 after RP11-19E11.1 after 18 and 24 h using LNA3. c Motif enrichment analysis in the RP11-19E11.1 promoter
for E2F transcription factor. d Chromatin immunoprecipitation (ChIP) using E2F1 antibody in HCC38. Two biological replicates are shown (two-
tailed unpaired t test). e RNA levels of CCNE2 and RP11-19E11.1 in HCC38 and SUM149PT after exogenous overexpression of E2F1 (two-tailed
paired t test). Each point represents a single measurement. Data are presented as mean ± SEM. *P < 0.05; **p < 0.01; ***p < 0.001.
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trafﬁcking pathways. Its inhibition disrupts endomembrane
transport and retroviral release from infected cells.34
To validate the compounds identiﬁed in this screening, we
selected three top/bottom cell lines after ranking our qRT-PCR
results for RP11-19E11.1 levels. Time of treatment and viability
assessment by metabolic assays were performed using methods
similar to those employed in the screening. We found that neither
PAC-1 nor YM201636 showed the tendency observed in the
screening for the cell lines tested (Supplementary Fig. 6a, b).
Enzastaurin, on the other hand, showed the expected results in all
cell lines tested, except for SUM149PT (Supplementary Fig. 6c).
Therefore, we decided to include another cell line with moderate
levels of RP11-19E11.1, MDA-MB-468. Here, we reproduced the
results observed in the screening, as a signiﬁcant negative
correlation (p value 0.044) was observed between RP11-19E11.1
levels and sensitivity to enzastaurin (Fig. 7d). IC50 values showed the
same tendency observed in the screening but was not signiﬁcant.
These results are quite provocative, as PKC activity leads to the
activation of several pathways that can modulate a number of
cellular processes, including proliferation and anti-apoptotic signal-
ing.35 Among others, PKC can activate Raf1 by direct phosphoryla-
tion that subsequently can lead to phosphorylation of Rb protein,
releasing E2F transcription factors.36 In addition, the disruption of
Raf1-Rb protein interaction leads to tumor growth and angiogenesis
inhibition.37 Furthermore, PKC can also activate Ras, which can
induce E2F1 expression.38 Therefore, PKC inhibition could be an
attractive target for further exploration in the treatment of basal
breast cancer patients with an E2F activation signature.
DISCUSSION
Several studies have shown that lncRNA expression can be used to
classify breast cancer into subtypes as effectively as PCGs,13,14,39,40
providing additional prognostic and predictive value.41 We
identiﬁed a cohort of clinically relevant lncRNAs that are
overexpressed in basal-like breast cancer as compared to normal
tissue and other breast cancer subtypes, and we suggest that this
signature may be useful in future studies aimed at understanding
the etiology and treatment of this aggressive tumor.
The consequences and mechanisms of lncRNA dysregulation in
basal-like/TNBC subtypes are not well deﬁned. Two studies
compared expression levels between TNBC vs. normal tissue using
lncRNA microarrays in a small cohort of patients,42,43 while another
study focused on breast cancer subtypes but did not take into
Fig. 7 Drug screening using lncRNA RP11-19E11.1 levels as predictive value. a Basal-like cell lines with drug sensitivity data available
ranked according to the expression of RP11-19E11.1 (obtained from CCLE.31) b Compounds identiﬁed with signiﬁcantly different sensitivity
(according to IC50 values) when comparing cell lines with low or high RP11-19E11.1 expressing levels. c Linear correlation between RNA
expression and drug sensitivity (IC50) for the compounds identiﬁed in b. Pearson’s correlation test was used. CAL-85-1 cell line is not included
(no expression data available). d Validation of the results for enzastaurin. Data are presented as mean ± SEM. *P < 0.05; **p < 0.01; ***p < 0.001
(unpaired t test unless speciﬁed).
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account lncRNA expression in normal tissue,40 as we have done in
our study. Furthermore, our studies are novel because we
intersected patient data with cell line RNA-seq data in an effort to
use clinical ﬁndings in in vitro studies for further functional and
mechanistic studies. Interestingly, two of our candidates have been
identiﬁed as basal-speciﬁc lncRNAs in previous studies, the CTD-
2015G9.2 and RP11-19E11.140,44 Another candidate that we
identiﬁed is MIR146, the lncRNA host gene for mir-146a, a microRNA
extensively studied and shown to play a role in TNBC/basal-like
breast cancer.45 We validated lncRNA expression using qRT-PCR to
conﬁrm the expression pattern reported by RNA-seq in different cell
line subtypes. Furthermore, we demonstrated that lncRNA ablation
exerted a major impact on cell proliferation and migration/invasion,
principal characteristics of the oncogenic signature.
We selected the lncRNA RP11-19E11.1 for further study in detail
because its OE correlates with poor prognosis in patients with
basal-like breast cancer. Importantly, its depletion impaired cell
proliferation and strongly induced apoptosis. While our manu-
script was in preparation, another group identiﬁed RP11-19E11.1
as a speciﬁc basal-like transcript in an independent cohort of
tumor samples.44 In that study, the authors showed that this
lncRNA was regulated through epigenetic modiﬁcations, in
agreement with our observations, but no detailed description of
the transcript, compartment localization, or putative function was
provided. Here, we identiﬁed and characterized at least three
RP11-19E11.1 transcript variants, correcting the actual Gencode
annotation. Importantly, we also revealed that the two main
lncRNA variants were chromatin-associated. Furthermore, by using
GSEA analysis in patients and in cell lines, we linked the lncRNA
expression to an E2F signature, demonstrating its connection to
E2F experimentally by ChIP. We also provided transcriptome-wide
analysis for three different cell lines after RP11-19E11.1 knock-
down, further strengthening the connections between ablation of
this lncRNA, activation of the DNA damage response, and
induction of apoptosis. Therefore, our work has substantially
expanded upon previous results, providing a better understanding
of the role of RP11-19E11.1 in basal-like breast cancer.
Basal-like breast cancers are generally poorly differentiated
tumors, are enriched in embryonic stem cell signatures, and show
activation of proliferation-associated factors.46 The E2F transcription
factors are well-known downstream effectors of the RB tumor
suppressor and have a pivotal role in regulating cell cycle
progression.47,48 They not only transcribe the subset of genes
necessary for the transition from G1 to S phase, but they also have a
role in controlling mitosis, DNA damage checkpoints and repair, and
apoptosis.47,48 E2Fs are known to affect cancer development,22 and
Rb dysfunction in TNBC is estimated to occur in ~30% of the cases.49
The inﬂuence of the E2F transcription factors in breast cancer
development is undisputed.23 In this study, we identiﬁed an E2F
oncogenic signature in patients with upregulated RP11-19E11.1
levels. Furthermore, our results showed RP11-19E11.1 to be an E2F1
target and a chromatin-associated lncRNA. Indeed, knock-down of
RP11-19E11.1 induced robust inhibition of DNA synthesis and
reduced expression of E2F target genes, which was followed by a
strong activation of DNA damage response and apoptotic pathways.
We showed that these effects could occur independently of p53.
Altogether, these results suggest that RP11-19E11.1 function could
be linked to that of E2F. Several examples of lncRNAs controlling cell
cycle can be found in the literature.50 For instance, ANRIL, an E2F1
target gene, promotes gene silencing by recruiting repressors to the
INK4 promoter. Another E2F1 target gene, H19/miR-67, seems to be
involved in pRB pathway inactivation. Therefore, in order to
elucidate the possible scenarios in which RP11-19E11.1 could be
involved in regulating cell cycle, future studies should investigate
RNA–DNA and RNA–protein interactions.
Patients with elevated RP11-19E11.1 expression shared a
speciﬁc oncogenic signature linked to poor prognosis. We
speculated that these patients would also show different
sensitivities to drug treatment. Taking advantage of drug screen-
ing published data in cell lines, we identiﬁed a PKC inhibitor as a
potential compound for further study. Notably, PKC not only
shares a connection to E2F activation but is also involved in key
steps of viral replication.51 The idea of virus-initiated breast cancer
has been proposed but is controversial. More compellingly, a
recently published study found that the expression of human
endogenous retrovirus-K is strongly associated with the basal-like
breast cancer, and a strong association with RB phosphorylation
and cell cycle activation was observed in these patients.52
In conclusion, this study identiﬁes clinically relevant basal-like
lncRNAs using a large cohort of samples from TCGA. Some of the
candidates identiﬁed may have prognostic value and may be
directly implicated in the oncogenic phenotype. Finally, we
characterized the lncRNA, RP11-19E11.1, identifying a novel
chromatin-associated and E2F target lncRNA. Our results show that
this lncRNA is necessary for cell cycle progression, and its ablation
impairs cell viability by inducing apoptosis. We also identiﬁed an
E2F-speciﬁc signature linked to the expression of RP11-19E11.1, and
have used cell lines expressing this lncRNA to identify possible drug
therapies, which could be tested in TNBC patients.
METHODS
TCGA data
The read count tables for all the sequencing samples (n= 1162) in TCGA
were downloaded from The National Cancer Institute’s Genomic Data
Commons (GDC). The count tables were normalized based on their library
size factors using DEseq2, and differential expression analysis was
performed. Clustering was performed using iCellR (https://github.com/
rezakj/iCellR) by selecting the dispersed genes running principal compo-
nent analysis and t-SNE. All the methylation β values for the samples with
Illumina 450 methylation array data (n= 892) were downloaded from GDC.
RNA-seq data processing
All the raw sequencing reads from our samples (Gene Expression Omnibus
(GEO) https://identiﬁers.org/geo:GSE138606 (2019)) and the cell lines down-
loaded from the GEO repository, https://identiﬁers.org/geo:GSE73526 (2016)
and https://identiﬁers.org/geo:GSE48213 (2013), were mapped to the human
reference genome (GRCh37/hg19) using the STAR aligner (v2.5.0c)54.
Alignments were guided by a Gene Transfer Format ﬁle. The mean read
insert sizes and their standard deviations were calculated using Picard tools
(v.1.126) (http://broadinstitute.github.io/picard). The read count tables were
generated using HTSeq (v.0.6.0)55 normalized based on their library size
factors using DEseq256 and differential expression analysis was performed.
The read per million normalized BigWig ﬁles were generated using BEDTools
(v.2.17.0)57 and bedGraphToBigWig tool (v.4). All downstream statistical
analyses and generating plots were performed in R environment (v.3.1.1)
(http://www.r-project.org/).
Cell culture
Breast cancer cells MDA-MB-231, Hs578T, MDA-MB-157, MDA-MB-468,
MCF7, SkBr3, and BT474 were cultured in Dulbecco’s modiﬁed Eagle’s
mMedium: Nutrient Mixture F12 (DMEM/F12) (Corning) supplemented with
10% fetal bovine serum (FBS), P/S (50 U/mL), and L-Glut (1%). SUM149PT
and SUM159PT were cultured with DMEM/F12 supplemented with 5% FBS,
P/S (50 U/mL), and L-Glut (1%), insulin (5 µg/mL), and hydrocortisone (1 µg/
mL). Breast cancer cells HCC2157, HCC38, HCC2157, BT549, HCC70,
HCC1143, and T-47D were cultured in RPMI medium supplemented with
10% FBS, P/S (50 U/mL), and L-Glut (1%). Normal breast MCF10A cells were
cultured in DMEM/F12 (Corning) medium supplemented with 5% horse
serum, epidermal growth factor (20 ng/mL), cholera toxin (100 ng/mL),
insulin (0.01 mg/mL), and hydrocortisone (500 ng/mL). All cells were
cultured at 37 °C with 5% CO2. All cell lines were obtained from ATCC,
except from SUM149PT and SUM159PT (gifted from Neel BG laboratory).
To ensure mycoplasma-free culture, cells were tested periodically using
the Universal Mycoplasma Detection Kit (ATCC, 30-1012K).
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RNA interference (siRNA and LNA) Protocol
siRNA at 20 nM (Dharmacon) or Antisense LNA GapmeRs at 25/50 nM
(Qiagen) transfection mix was prepared in OptiMEM (Gibco) and RNAiMAX
at 2.5 µL/mL (Invitrogen) for 10min at room temperature. Transfection mix
was then added to the cells at the time of seeding. After 6 h, the media
were replaced for fresh new media. siRNA and LNAs sequences are in
Supplementary Methods.
Cell transfection protocol
Cells were seeded in 6-well plates at a conﬂuence of 20–30%. Next day,
transfection mix was prepared using FuGene HD reagent (Promega) at 3:1
ratio with 1 µg of pCMV-E2F1 or pCDH-EGFP in OptiMEM. After 10min, the
mixture was added to the cells with a ﬁnal volume of 1mL in 0.5% DMEM/
F12 media. After 6 h, one volume of 10% FBS media was added. Next day,
transfection media was replaced for fresh media and cells were collected
for analysis after 48 or 72 h.
Cell fractionation
Nuclear/cytoplasmic fractionation was performed as described.53 Brieﬂy,
cells were rinsed three times with cold phosphate-buffered saline (PBS)
and scraped carefully. After spinning, disruption buffer (KCl 10 mM, MgCl2
1.5 mM, Tris-Cl, pH 7.5, 20 mM, and dithiothreitol (DTT) 1 mM) was added
and let to stand for 10min. A type B Dounce was used to disrupt the
cytoplasm using 10–15 strokes. When ~90% of the cytoplasm was broken,
0.1% of Triton X was added, mixed by inversion ﬁve times, and centrifuged
for 5 min at 1500 r.p.m. The supernatant containing the cytoplasmic
fraction was recovered by this method. Both supernatant and nuclei
(pellet) were processed for RNA extraction using the SurePrep Nuclear or
Cytoplasmic RNA Puriﬁcation Kit (Fisher, BP2805-50) following user manual
instructions. DNAaseI treatment was performed for both fractions (Norgen
Biotek cat. num. 25710).
Chromatin precipitation
Cell fractionation was performed as described above. The pellet
containing the nuclear fraction was then resuspended in 125 μL of cold
NUN1 buffer (20 mM Tris-HCl, 75 mM NaCl, 0.5 mM EDTA, 50% glycerol)
and transferred to a new Eppendorf. Then, 1.2 mL of cold NUN2 buffer
(20 mM HEPES-KOH, pH 7.6, 300 mM NaCl, 0.2 mM EDTA, 7.5 mM MgCl2,
1% NP40, 1 M urea) was added and vortexed. Samples were kept on ice
for 15 min, vortexing every 3–4 min. Chromatin was recovered by
centrifuging at 16,000 × g for 10 min at 4 °C. RNA was extracted from the
supernatant fraction using TRIzol LS (Invitrogen) and for the chromatin
fraction with TRIzol (Invitrogen).
Reverse transcription and quantitative real-time PCR
Total RNA was isolated using the TRIzol reagent (Fisher). RNA was
quantiﬁed with NanoDrop (Thermo Scientiﬁc) and RNA was reverse
transcribed using Verso cDNA Synthesis Kit (Thermo Scientiﬁc). Quantita-
tive reverse transcription PCR was performed using CFX96 Touch Real-Time
PCR Detection System (Bio-Rad). Relative quantity of expression was
calculated with the ΔΔCt method using GAPDH as an internal control.
Primer sequences are in Supplementary Methods.
Protein extraction and Western blot
Cells were trypsinized and washed with PBS. The pellet was then
resuspended in fresh ELB buffer (50mM HEPES, pH 7, 150mM NaCl, 5mM
EDTA, 0.1% NP40, 10% glycerol) supplemented with a protease and
phosphatase inhibitor cocktail (1mM DTT, 0.5mM AEBSF (4-(2-aminoethyl)
benzenesulfonyl ﬂuoride hydrochloride), 2 μg/mL leupeptin, 2 μg/mL apro-
tinin, 10mM NaF, 50mM β-glycerophosphate). Twenty micrograms of
protein was loaded in a 10–15% acrylamide gels. Primary antibodies were
diluted in 3% bovine serum albumin TBS-T (Tris-buffered saline with Tween-
20) and incubated O/N at 4 °C. The primary antibody used and dilutions are
α-tubulin (Sigma T5168, 1:5000), E2F1 (CST #3742, 1:1000), E2F3 (GeneTex
GTX11843, 1:2000), p21 (CST #2947, 1:1000), P53 (Santa Cruz FL-393, 1:1000),
p-P53 (CST #9286, 1:1000), γH2AX (CST #9718, 1:1000). All blots were derived
from the same experiment and were processed in parallel. Un-cropped blots
can be found in the Supplementary information ﬁle.
FACS analysis
For EdU and cell cycle analysis, Click-iT EdU Alexa Fluor 488 Kit was used
(Invitrogen C10337) following the manufacturer’s instructions.
Annexin-V staining was performed using Annexin-V Kit (Mileny Biotec,
130-092-052) following the manufacturer’s instructions. All analyses were
performed with LSRII UV cell analyzer (BD Bioscience) and FlowJo software.
Viability assays and compounds
For drug sensitivity evaluation, cells were seeded in a 96-well plate at 4000
cells/well. The next day, cells were incubated at 37 °C with different
concentrations of the test compounds. Control cultures were incubated
with dimethyl sulfoxide (DMSO). After 48 or 72 h, media were replaced
with fresh media supplemented with MTT (Sigma) at a ﬁnal concentration
of 0.5 mg/mL. After 1.5 h, media were removed and formazan crystals were
dissolved with 100 μl of DMSO. Absorbance at 570 nM was read in the
spectrophotometer (TECAN Inﬁnite M200). The drugs used in this assay
were PAC-1 (S2738, Selleckchem), YM201636 (ref. 13576, Cayman
Chemical), and enzastaurin (ref. HY-10342, MedChemExpress).
For viability assays after RNA interference, cells were seeded at 4000
cells/well and transfected at the same time as explained in the previous
section. After 6 h, media were replaced with fresh new media. MTT assay
was performed as explained above each day and viability was compared to
T0. All experiments were repeated at least three times with different cell
passage number, with three replicates per experiment.
Rapid ampliﬁcation of cDNA ends
Nuclear RNA was isolated from HCC2157 cells lines following the protocol
described above. RACE was performed using the SMARTer RACE 5′/3′ Kit
(Clontech) as per the manufacturer’s instructions. Primers were designed at
known regions of the transcripts in order to achieve accurate 5′ or 3′ ends
(Supplementary Methods).
Chromatin immunoprecipitation
ChIP was performed following the previous described method with some
modiﬁcations58. Nuclei were obtained from 1 × 107 HCC38 cells and cross-
linked with 1% formaldehyde. Sonication was performed with Branson
Soniﬁer 450 on ice to obtain an average DNA length of 400–600 bp. The
equivalent of 25 µg DNA was used per ChIP reaction. Chromatin was pre-
cleared with protein A and then incubated with 2 μg of each antibody,
E2F1 and IgG (Millipore #17-10061 Crosslinks) O/N. Chromatin was
resuspended in 200 μL of 10mM Tris, pH 8.0 buffer, and enrichment was
assayed by quantitative PCR. Primers used are described in Supplementary
Methods.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The raw RNA-sequencing data (supporting Fig. 1) used during the study are publicly
available in the NCBI Gene Expression Omnibus (GEO) repository: https://identiﬁers.
org/geo:GSE73526 and https://identiﬁers.org/geo:GSE48213. The read count tables
(Supporting Figs 1–4) for all the sequencing samples (n= 1162) in TCGA are publicly
available at The National Cancer Institute’s (NCI) Genomic Data Commons (GDC)
(https://portal.gdc.cancer.gov/). RNA-sequencing datasets (Supporting Figs 3–6)
generated during the current study are publicly available in the GEO repository:
https://identiﬁers.org/geo:GSE138606. The Drug sensitivity in Breast Cancer Cell lines
data (Supporting Fig. 7) are publicly available at https://www.cancerrxgene.org/
downloads/drug_data?tissue=BRCA. Additional datasets used and generated during
the study will be made available on request from the corresponding author, Prof.
Francisco J. Esteva, as described in the following metadata record: https://doi.org/
10.6084/m9.ﬁgshare.1026652759.
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